{"id":"abciximab-ufh","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Bleeding"},{"rate":"1-2","effect":"Thrombocytopenia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Back pain"}]},"_chembl":{"chemblId":"CHEMBL1201584","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abciximab irreversibly binds to the glycoprotein IIb/IIIa receptor on platelets, preventing fibrinogen-mediated platelet cross-linking and aggregation. UFH provides systemic anticoagulation by potentiating antithrombin III. Together, this combination reduces thrombotic complications during coronary angioplasty and stent placement.","oneSentence":"Abciximab is a monoclonal antibody that blocks platelet glycoprotein IIb/IIIa receptors to prevent platelet aggregation, combined with unfractionated heparin (UFH) for anticoagulation during percutaneous coronary intervention.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:34.820Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome undergoing percutaneous coronary intervention"},{"name":"Prevention of ischemic complications during coronary angioplasty"}]},"trialDetails":[{"nctId":"NCT01087723","phase":"PHASE3","title":"European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2010-03","conditions":"Acute Coronary Syndrome","enrollment":2198},{"nctId":"NCT01433627","phase":"PHASE3","title":"Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX","status":"UNKNOWN","sponsor":"Italian Society of Invasive Cardiology","startDate":"2011-10","conditions":"Acute Coronary Syndromes, STEMI, NSTEMI","enrollment":7200},{"nctId":"NCT00373451","phase":"PHASE4","title":"Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2006-07","conditions":"Myocardial Infarction, Coronary Disease","enrollment":1721},{"nctId":"NCT00262054","phase":"PHASE4","title":"Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2005-11","conditions":"Coronary Disease, Angina Pectoris","enrollment":4570}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ReoPro"],"phase":"marketed","status":"active","brandName":"Abciximab + UFH","genericName":"Abciximab + UFH","companyName":"Deutsches Herzzentrum Muenchen","companyId":"deutsches-herzzentrum-muenchen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abciximab is a monoclonal antibody that blocks platelet glycoprotein IIb/IIIa receptors to prevent platelet aggregation, used in combination with unfractionated heparin (UFH) for anticoagulation during percutaneous coronary intervention. Used for Acute coronary syndrome undergoing percutaneous coronary intervention, Prevention of ischemic complications during coronary angioplasty.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}